Neumiller Joshua J, Bajaj Mandeep, Bannuru Raveendhara R, McCoy Rozalina G, Pekas Elizabeth J, Segal Alissa R, ElSayed Nuha A
Department of Pharmacotherapy, Washington State University, Spokane, WA.
Department of Medicine, Baylor College of Medicine, Houston, TX.
Diabetes Care. 2025 Feb 1;48(2):177-181. doi: 10.2337/dci24-0091.
The use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA (GIP/GLP-1 RA) classes has increased substantially over the past several years for treating type 2 diabetes and obesity. Increased demand for these pharmacotherapies has resulted in temporary product shortages for both GLP-1 RA and dual GIP/GLP-1 RA medications. These shortages, in part, have led to entities producing and marketing compounded formulations that bypass regulatory measures, raising safety, quality, and efficacy concerns. Even as shortages resolve, compounded GLP-1 RA and GIP/GLP-1 RA products continue to be heavily marketed to people with diabetes and obesity. The purpose of this statement by the American Diabetes Association is to guide health care professionals and people with diabetes and/or obesity in these circumstances of medication unavailability to promote optimal care and medication use safety.
在过去几年中，胰高血糖素样肽1受体激动剂（GLP-1 RA）以及双重葡萄糖依赖性促胰岛素多肽（GIP）和GLP-1 RA（GIP/GLP-1 RA）类药物在治疗2型糖尿病和肥胖症方面的使用大幅增加。对这些药物疗法需求的增加导致GLP-1 RA和双重GIP/GLP-1 RA药物出现暂时的产品短缺。这些短缺在一定程度上导致一些机构生产和销售绕过监管措施的复方制剂，引发了对安全性、质量和疗效的担忧。即使短缺问题得到解决，复方GLP-1 RA和GIP/GLP-1 RA产品仍继续大力向糖尿病和肥胖症患者推销。美国糖尿病协会发表本声明的目的是在药物无法获得的情况下，指导医疗保健专业人员以及糖尿病和/或肥胖症患者，以促进最佳护理和药物使用安全。
